Infectious Disease Control

TVM Capital Healthcare Announces Investment in Human Longevity, Inc. as Part of its Strategy of Supporting Disease Prevention and Healthy Aging

HLI is one of the most established, global longevity science companies and committed to accelerating living to 100+ years of a healthy, active, and mobile life DUBAI, UAE and RIYADH, Saudi Arabia, Sept. 18, 2024 /PRNewswire/ -- TVM Capital Healthcare, an international healthcare expansion and gr...

2024-09-18 16:00 1440

Hyundai Bioscience announces XAFTY®, a groundbreaking broad-spectrum antiviral capable of treating COVID-19, mpox, and dengue

* Hyundai Bioscience presents development updates of its broad-spectrum antiviral at the "Disease Prevention and Control Summit 2024" held in Philadelphia, USA.  SEOUL, South Korea, Sept. 11, 2024 /PRNewswire/ -- Dr. Heung-Jeong Woo, a vice president of Hyundai Bioscience shared insights on the...

2024-09-11 14:25 1136

Hyundai Bioscience to conduct phase 3 clinical trial for high-risk group of COVID-19 patients with the goal of emergency use authorization

* "Xafty® can be the only oral COVID-19 treatment that can be prescribed to high-risk group patients who cannot take Paxlovid®" * "While maintaining the current process for emergency use authorization for mild-to-moderate COVID-19 patients, Hyundai Bioscience will expedite Phase 3 clinical tr...

2024-08-28 17:29 1205

Hyundai Bioscience succeeds in developing 'Multi-treatment for mosquito-borne viral infections' including Dengue Fever

* Developed a 'Niclosamide-based multi-treatment drug' that can simultaneously treat mosquito-borne viral infections such as four serotypes of dengue virus, Zika, Chikungunya, and Yellow Fever. * Accelerating preparations for dengue fever basket clinical trial scheduled to be conducted inBraz...

2024-06-26 09:17 1713

Fosun Pharma's Self-developed Artemisinin Medicines Inject New Impetus to Malaria Prevention and Treatment in Africa

SHANGHAI, April 26, 2024 /PRNewswire/ -- World Malaria Day is marked each year onApril 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024Accelerating the fight against malaria for a more equitable world. WHO stated that malaria not only continues to directly endanger...

2024-04-26 12:39 1535

Hyundai Bioscience's antiviral for Dengue Fever to enter clinical trials in Brazil

* "Aiming to offer a Dengue antiviral treatment course in $100 price range" * Hyundai Bioscience decides to conduct dengue clinical trials in Brazil, which has the largest number of Dengue patients and offers a fast-track approval SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Biosc...

2024-04-25 21:41 1507

Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization

SEOUL, South Korea, April 18, 2024 /PRNewswire/ -- South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi,www.hyundaibioscience.com ) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue...

2024-04-19 10:54 2279

A Korean UV Sensor Manufacturer, Genicom Introduces Breakthrough Far UV & VUV Optical Sensor for Safe and Efficient Pathogen Control

SEOUL, South Korea, Jan. 31, 2024 /PRNewswire/ -- The COVID-19 pandemic is an ongoing challenge of emerging and re-emerging infectious pathogens. Ultraviolet (UV) has high energy in the wavelength range of 100 ~ 400nm and is used for sterilization, air purification, medical treatment, etc. by bre...

2024-01-31 22:00 1545

GPN Vaccines Reports Positive Safety and Immunogenicity Data from its Phase 1 Trial of Gamma-PN

ADELAIDE, Australia, Jan. 3, 2024 /PRNewswire/ -- GPN Vaccines Ltd, a clinical-stage biotechnology company developing a Streptococcus pneumoniae vaccine to prevent life-threatening pneumonia, bacteraemia and meningitis, is pleased to announce positive safety and immunogenicity data from its Phase...

2024-01-04 04:30 1861

Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for A New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs

SHANGHAI, Dec. 14, 2023 /PRNewswire/ -- The Japan-based Global Health Innovative Technology Fund (GHIT Fund) announced today that it will invest approximatelyUS$3.3 million (approximately 500 million yen[1]) in a global multicenter Phase III clinical trial project (the "Program") led by Fosun Ph...

2023-12-14 17:00 3877

MicuRx announces poster presentation and participation in ID Week 2023 Conference

FOSTER CITY, Calif., Oct. 11, 2023 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, announces that a poster on our preclinical product, MRX-6038, will be p...

2023-10-11 23:33 1744

GC Biopharma to Produce Cholera Vaccines Jointly with Eubiologics

YONGIN, South Korea, Aug. 25, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed a MOU at its headquarters in Yongin,South Korea with Eubiologics for a co-production of Euvichol, an oral cholera vaccine. Under the MOU, bo...

2023-08-25 15:14 1624

AI-based wastewater sampling predicts COVID pressure on hospitals

SYDNEY, Aug. 7, 2023 /PRNewswire/ -- New research shows it is possible to accurately predict hospital admission numbers due to COVID-19 up to four weeks in advance with an Artificial Intelligence (AI) based system using COVID wastewater sampling.

2023-08-07 21:13 1640

AmCham South China Study - Business Confidence in China Rising, Increases in Investment Plans Observed

GUANGZHOU, China, Aug. 1, 2023 /PRNewswire/ -- The American Chamber of Commerce inSouth China (AmCham South China)  released its 2023 Mid-Year Report on Impact of COVID Policy Change. The study shows slow but steady improvement in business sentiment, investments, and activities in the first half ...

2023-08-02 09:00 1319

GC Biopharma's "GC FLU" obtains vaccine approval in Egypt: First-ever approval of the company's quadrivalent flu vaccine on the African continent

* Striving to further expand its territory to Africa and the Middle East from Southeast Asia and Latin America * "Will create synergy between international procurement market and private markets of individual countries so as to boost sales and profitability" YONGIN, South Korea, July 21, 2023...

2023-07-21 16:47 2013

BGI CEO Yin Ye Advocates for Global Technology Sharing

SHENZHEN, China, July 5, 2023 /PRNewswire/ -- Speaking on a panel at the 10th Arab-China Business Conference inRiyadh, Saudi Arabia, Dr Yin Ye, BGI Group CEO, reinforced the importance of making technological advancements available to everyone through scientific sharing to benefit humanity. "We ...

2023-07-05 14:17 1849

Fosun Pharma and IFC Partner to Improve Access to High Quality Medicines in Africa

ABIDJAN, Côte d'Ivoire, June 6, 2023 /PRNewswire/ -- To support stronger healthcare delivery and outcomes inWest Africa, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma or the Company, stock code: 600196.SH; 02196.HK) today announced a deepening partnership with IFC to help the comp...

2023-06-06 19:52 2657

SK bioscience Presents Solution for Equitable Access of Vaccine at Regionalized Vaccine Manufacturing Collaborative of World Economic Forum

* Jaeyong Ahn, CEO of SK bioscience, presents the 'Glocalization' project to secure the global vaccine accessibility, claiming the importance of international cooperation to establish a regional-based vaccine hub at the Regionalized Vaccine Manufacturing Collaborative Side Event. SEONGNAM, Sout...

2023-05-23 20:00 2085

Recall Notice - SD Biosensor, Inc. requests discontinuation of use and disposal of specific Pilot™ COVID-19 At-Home Tests in the United States due to microbial contamination in the liquid buffer solution

SEOUL, South Korea, May 4, 2023 /PRNewswire/ -- SD Biosensor, Inc. today is requesting that consumers stop using and dispose of specific Pilot COVID-19 At-Home Tests inthe United States because potentially harmful bacteria were found in the tube with liquid inside (pouch 2 of the kits). The affe...

2023-05-05 04:00 2226

iNtRON confirms cancer-controlling effect of PHAGERIA® drug candidate in the organoid model.

* Secured the effectiveness confirming data of PHAGERIA® technology for colorectal cancer organoids * The first target cancer type of PHAGERIA® technology is colorectal cancer (CRC) BOSTON and SEOUL, South Korea, April 3, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON",www.intodeworld.com...

2023-04-04 10:33 2188
12345 ... 13

Week's Top Stories